深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2024-021 深圳市理邦精密仪器股份有限公司 关于第二期员工持股计划存续期展期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）于 2024 年 7 月 30 日召开第五届董事会 2024 年第三次会议审议通过了《关于公司第二期员工持股 计划存续期展期》的议案，该议案已于 2024 年 7 月 19 日召开的公司第二期员工 持股计划 2024 年第一次持有人会议审议通过，现将有关事项公告如下： 一、公司第二期员工持股计划基本情况 公司于 2021 年 6 月 30 日召开的第四届董事会 2021 年第四次会议及第四届 监事会 2021 年第四次会议，于 2021 年 7 月 19 日召开的 2021 年第一次临时股 东大会审议分别通过了《关于公司第二期员工持股计划（草案）及其摘要》的议 案，同意公司实施第二期员工持股计划（以下简称"第二期员工持股计划"）。 第二期员工持股计划的存续期限为 36 个月，自第二期员工持股 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2024-018 深圳市理邦精密仪器股份有限公司 第五届董事会 2024年第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会 2024 年第二次会议于 2024 年 4 月 25 日（星期四）10:00 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2024 年 4 月 19 日 以电子邮件方式发出。会议应出席董事 7 名，实际出席董事 7 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由董事长张浩先生主持，出席 会议的董事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《2024 年第一季度报告》的议案 经审核，董事会认为公司编制的《2024 年第一季度报告》真实、准确、完整， 不存在任何虚假记载、误导性陈述或者重大遗漏。 公司董事会审计委员会已审议通过了该议案。 表决结果：同意 7 票，反对 0 票，弃权 0 票，获得通过。 特此 ...

Financial Performance - The company's revenue for Q1 2024 was ¥443,644,512.37, a decrease of 30.65% compared to ¥639,691,149.30 in the same period last year[4] - Net profit attributable to shareholders was ¥38,517,609.83, down 72.56% from ¥140,387,548.35 year-on-year[4] - Basic earnings per share decreased by 72.58% to ¥0.0664 from ¥0.2422 in the same period last year[4] - Operating profit for Q1 2024 was CNY 38.95 million, down 75.0% from CNY 155.65 million in Q1 2023[33] - The company recorded a total comprehensive income of CNY 38.89 million, a decrease of 72.1% from CNY 139.89 million in Q1 2023[33] Cash Flow - The net cash flow from operating activities increased by 112.19% to ¥77,719,605.62, compared to ¥36,627,250.07 in the previous year[21] - The company reported a net cash flow from operating activities of CNY 77.72 million, an increase of 112.2% compared to CNY 36.63 million in the previous year[35] - Cash outflow from investing activities was CNY 209.43 million, significantly higher than CNY 9.05 million in the previous year, indicating increased investment activity[35] - The net cash flow from financing activities was -2,285,328.30 CNY, compared to -1,351,604.00 CNY in the previous year, indicating a decline in financing activities[36] - The net increase in cash and cash equivalents for the quarter was -132,303,204.09 CNY, contrasting with an increase of 24,049,362.40 CNY in the same period last year[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,241,044,893.58, an increase of 1.24% from ¥2,213,670,947.74 at the end of the previous year[4] - The company's total liabilities decreased to CNY 238,280,919.02 from CNY 249,797,977.83, reflecting a decline of approximately 4.6%[30] - Total current liabilities decreased to CNY 207,153,376.78 from CNY 215,480,396.58, a decrease of about 3.0%[30] - Non-current assets totaled CNY 657,157,704.44, slightly down from CNY 658,285,261.84[30] - The company's equity remained stable at CNY 581,721,846.00, unchanged from the previous period[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,367[24] - The largest shareholder, Zhang Hao, holds 20.98% of the shares, totaling 122,038,160 shares[25] Operational Efficiency - The company reported a significant decrease in operating costs by 33.52%, amounting to ¥178,928,457.42 compared to ¥269,126,826.78 last year[11] - Other income decreased by 59.64% to ¥8,413,242.05 from ¥20,844,575.86 year-on-year[12] - Research and development expenses for Q1 2024 were CNY 84.05 million, an increase of 6.0% compared to CNY 78.60 million in Q1 2023[32] Strategic Focus - The company is focusing on new product development and market expansion strategies to enhance future growth prospects[28]

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2024-019 深圳市理邦精密仪器股份有限公司 深圳市理邦精密仪器股份有限公司 1、审议通过《2024 年第一季度报告》的议案 经审核，监事会认为董事会编制和审核公司《2024 年第一季度报告》的程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《2024 年第一季度报告》及《2024 年第一季度报告披露提示性公告》详见 巨潮资讯网，《2024 年第一季度报告披露提示性公告》同时刊载于中国证券报、 证券时报。 表决结果：同意 3 票，反对 0 票，弃权 0 票，获得通过。 特此公告。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 第五届监事会 2024年第二次会议决议公告 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届监事会 2024 年第二次会议于 2024 年 4 月 25 日（星期四）11:30 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2024-016 深圳市理邦精密仪器股份有限公司 2023年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、深圳市理邦精密仪器股份有限公司（以下简称"公司"） 专用账户中股份 为 2,058,500 股。因回购股份不参与分红，公司以现有总股本 581,721,846 股剔除 回购股份 2,058,500 股后的 579,663,346 股为基数进行权益分派。 2、本次现金分红总额=实际参与现金分红的股本×每 10 股分红金额÷10 股 =579,663,346 股×2.07 元÷10 股=119,990,312.62 元；按公司总股本折算每股现金 红利=现金分红总额÷现有总股本=119,990,312.62 元÷581,721,846 股=0.2062675 元/股。 3、本次权益分派实施后的除权除息价格（元/股）=股权登记日收盘价- 0.2062675 元/股。 一、 股东大会审议通过利润分配方案情况 公司 2023 年年度权益分派方案 ...

法律意见书 北京市中伦（深圳）律师事务所 关于深圳市理邦精密仪器股份有限公司 2023年度股东大会的 法律意见书 致：深圳市理邦精密仪器股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、《上市公司股东大会规 则》（下称"《股东大会规则》"）等有关法律法规的规定及公司现行章程（下称"《公 司章程》"）的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受深 圳市理邦精密仪器股份有限公司（下称"公司"）的委托，指派律师出席公司 2023 年度股东大会（下称"本次股东大会"），并就本次股东大会的召集和召开程序、 召集人资格、出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意 见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料和口头证言均符合真实、准 确、完整的要求，有关副本、复印件等材料与原始材料一致。 本法律意见书仅就本次股东大会的召集和召开程序是否符合法律、行政法规 及《公司章程》的规定，以及出席、列席本次股东大会人员的资格、召集人资格、 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2024-015 深圳市理邦精密仪器股份有限公司 2023年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更前次股东大会决议的情形。 3、根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的有关 规定，上市公司回购专用账户中的股份，不享有股东大会表决权、利润分配、公积 金转增股本、认购新股和可转换公司债券等权利，不得质押和出借。截至股权登记 日（2024 年 4 月 16 日），公司回购专用账户股份数量为 2,058,500 股，故本次股 东大会有表决权总股数为 579,663,346 股。 一、会议召开情况 1、现场会议时间：2024 年 4 月 22 日（星期一）下午 15:30。 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 4 月 22 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00； 6 ...

关于召开 2023 年度股东大会的提示性公告 3、会议召开的合法、合规性： 公司于 2024 年 3 月 28 日召开的第五届董事会 2024 年第一次会议审议通过 了《关于提请召开 2023 年度股东大会》的议案，本次会议的召开程序符合有关 法律法规要求以及《公司章程》的规定。 关于召开2023年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）于 2024 年 3 月 29 日 在中国证监会指定的创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披 露了《关于召开 2023 年度股东大会的通知》（公告编号：2024-010）。本次股东 大会采用现场投票和网络投票相结合的方式召开，现将本次股东大会的有关事宜 提示如下： 一、 召开会议的基本情况 1、 股东大会届次：2023 年度股东大会 2、 股东大会的召集人：公司第五届董事会 证券代码：300206 证券简称：理邦仪器 公告编号：2024-014 深圳市理邦精密仪器股份有限公司 4、会议召开方式：采用现场表决与网络投 ...

理邦仪器（300206） | --- | --- | --- | --- | --- | --- | |------------------------------|--------|--------|--------|--------|--------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 1,742 | 1,938 | 2,182 | 2,441 | 2,738 | | 同比 | 6.48% | 11.22% | 12.59% | 11.88% | 12.14% | | 归母净利润（百万元） | 232.94 | 221.30 | 298.11 | 346.08 | 390.89 | | 同比 | 0.65% | -5.00% | 34.71% | 16.09% | 12.95% | | EPS- 最新摊薄（元 / 股） | 0.40 | 0.38 | 0.51 | 0.59 | 0.67 | | P/E （现价 & 最新摊薄） | 27.27 | 28.70 | 21.31 | 18 ...

Financial Performance - The company's operating revenue for 2023 reached ¥1,937,988,917, representing an increase of 11.22% compared to ¥1,742,412,290 in 2022[32]. - Net profit attributable to shareholders for 2023 was ¥221,301,109, a decrease of 5.00% from ¥232,987,942 in 2022[32]. - The net profit after deducting non-recurring gains and losses was ¥194,472,721, down 3.19% from ¥200,922,822 in the previous year[32]. - The net cash flow from operating activities decreased significantly by 54.96% to ¥150,964,260 from ¥335,157,849 in 2022[32]. - Basic earnings per share for 2023 were ¥0.3818, reflecting a decline of 5.00% compared to ¥0.4020 in 2022[32]. - Total assets at the end of 2023 amounted to ¥2,213,670,947, a slight decrease of 0.98% from ¥2,235,526,840 at the end of 2022[32]. - The net assets attributable to shareholders increased by 6.06% to ¥1,965,276,976 from ¥1,853,056,780 in the previous year[32]. - The company achieved a total revenue of 1,937.99 million yuan in 2023, representing a year-on-year growth of 11.22%[97]. - Domestic market revenue reached 979.26 million yuan, with a year-on-year increase of 15.99%, while international market revenue was 958.73 million yuan, growing by 6.74%[97]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2023, representing a year-over-year growth of 12%[171]. Product Development and Innovation - The company launched several industry-leading products, including the iX10 Neo neonatal monitor and the AX8 and AX9 ultrasound devices, showcasing its commitment to innovation[6]. - The company is focusing on the development of high-sensitivity magnetic sensors and advanced biochemical target binding methods for its new products[32]. - The company launched the new generation iV series plug-in monitor in 2023, integrating multiple advanced monitoring technologies, enhancing its competitive advantage in the critical care market[58]. - The company has developed the industry-first CNBP continuous non-invasive blood pressure measurement technology, widely accepted by top-tier hospitals[59]. - The company’s blood gas and biochemical analyzers are at the international leading level, contributing to its comprehensive competitive strength in the in vitro diagnostics sector[54]. - The company’s IVD products include high-end microfluidic POCT products, routine testing products, and molecular diagnostic products, with the CL30 fully automated nucleic acid detection analyzer being the first molecular diagnostic product launched[74]. - The i500 fully automated blood gas electrolyte analyzer is expected to be launched in Q1 2024, aiming to disrupt the blood gas market dominated by imported brands[77]. - The company is committed to continuous investment in the IVD field, focusing on product performance enhancement and diversification to strengthen its competitive advantage[81]. - The company launched new blood gas products, which will enhance the variety and total capacity of its product line[125]. - The company is focusing on enhancing its market presence with new product registrations, including a blood oxygen sensor approved on September 17, 2023[163]. Market Expansion and Strategy - The newly established subsidiary in Peru is part of the company's global expansion strategy, with a total of eight overseas subsidiaries now in operation[7]. - The company aims to deepen its localization strategy in international markets and enhance its marketing and sales efforts[7]. - Future outlook includes expanding market presence and enhancing product offerings in the Point of Care Testing (POCT) segment[32]. - The company is expanding its market presence, targeting an increase in sales in Southeast Asia, with a goal of capturing 15% market share by 2025[162]. - The company is actively pursuing regulatory approvals for its new products, ensuring they meet the necessary standards for market entry[166]. - The company is exploring strategic acquisitions to bolster its technology capabilities and market reach[177]. - The company has completed a strategic acquisition of a competitor, which is expected to contribute an additional 300 million RMB in annual revenue[171]. Research and Development - R&D investment for the reporting period was CNY 347.43 million, an increase of 16.77% year-on-year, accounting for 17.93% of total revenue[102]. - The number of R&D personnel increased by 6.19% to 789 in 2023, accounting for 29.28% of the total workforce, up from 27.41% in 2022[146]. - The company has a robust pipeline of medical devices with various registration statuses, indicating a strong commitment to compliance and market readiness[166]. - The company is investing 200 million RMB in R&D for new technologies aimed at improving diagnostic accuracy and efficiency[171]. - The company is focusing on integrating new technologies such as cloud computing, IoT, AI, and 5G to explore new business models in remote and internet healthcare[86]. Awards and Recognition - The company received multiple industry awards, including the title of "Leading Enterprise in High-Quality Development" in 2023[6]. - The company has received multiple accolades for its patents, including being recognized as a national intellectual property advantage enterprise in 2022[102]. - The company has achieved IVDR CE certification for 16 product series and MDR CE certification for 64 product series by the end of 2023, enhancing its market access in Europe[149]. Customer Engagement and Service - The company has established a service network that covers over 50,000 medical institutions in China and has a global presence in over 170 countries and regions[56]. - The company’s after-sales service system has been upgraded to provide 24/7 support across more than 170 countries, ensuring customer satisfaction[107]. - The company achieved a 95% customer satisfaction rate, reflecting strong product performance and service quality[177]. - The company has conducted nearly 800 training sessions through its academic platform, reaching over 220,000 medical professionals and enhancing its brand influence[121].